Nice & Green extends its support to the Swiss biotech Evolva with additional financing of CHF 12M
Nice & Green, the Swiss investment firm, commits to additional funding of CHF 12 million as part of its investment partnership with Evolva, the Swiss biotech company focused on the research, development and commercialization of products based on nature.
The extended agreement between Nice & Green and Evolva will be unfolded through the issuing of convertible notes under agreed-upon terms until the end of 2023. The total available funds to date – up to CHF 28 million – will allow Evolva to accelerate its growth and will be deployed to support its commercial operations and product launches in key markets, as well as to fund the further development of the company’s product pipeline.
About Evolva
Evolva is a Swiss biotech firm that focuses on the research, development, and commercialization of natural ingredients. A market leader in Flavors and Fragrances, Health Ingredients, and Health Protection. Evolva’s workforce, half of whom are women, is committed to creating goods that promote health, well-being, and sensory delight. Find out more at evolva.com.
About Nice & Green
Nice & Green is a privately held Swiss investment firm providing innovative and tailor-made alternative financing solutions for small and mid-sized listed companies. Nice & Green helps ambitious companies secure funding needed for their growth and strives to establish long term financial partnerships with them. Find out more at nicengreen.ch.
Contact Information
Michèle Aouad
Head of Marketing & Communications
maouad@nicengreen.ch
+41 (0)22 361 36 97